SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GLGC Gene Logic
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Lokness who wrote (32)1/25/1999 6:25:00 PM
From: Mike McFarland  Read Replies (1) of 360
 
GLGC just recently made the announcement of
the agreement with AFFX to use their (AFFX) chip
and so I wonder what GLGC plans is the market/use
for the flow through chip.

What I got from Dr. Brennen's talk was that they
only put something on the order of 100 "important"
genes on the flow through chip--whereas while the
affx chip has it's place, the fact that it has 50,000
data points on it makes it a lot more expensive--
and maybe it is slow too...

Regarding chips, Brennen also said that the
flow through chip is something like 40 times
faster...very important for high throughput
screening...and that they "will have profiling
chips shortly".

--Mike
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News